

MODERNA'S CLINICAL LABORATORIES ARRIVE AT HARWELL CAMPUS

The state-of-the art labs will help improve and accelerate the drug development process and contribute towards discovery of new mRNA vaccines and therapeutics.

The clinical laboratories were constructed in Northumberland and transported to the Harwell Science and Innovation Campus in Oxfordshire by a convoy of 52 lorries over several weeks.

LONDON, UK.—(ACCESS WIRE)— 22 November, 2023—[Moderna, Inc.](#) (Nasdaq: MRNA) has completed the installation of its state-of-the-art clinical laboratories into its Moderna Innovation and Technology Centre (MITC), located at Harwell Science and Innovation Campus in Oxfordshire.

The clinical biomarker, bioanalytical and molecular assays laboratories will process samples from Moderna's clinical trials across the UK and Europe. They will enable Moderna to rapidly evaluate clinical data on the effectiveness of potential therapeutics and vaccines, as part of its ambition to bring mRNA manufacturing and research to UK shores and provide the public with access to pandemic response capabilities.

Once operational, the facility will store clinical samples in an automated, custom-built biobank. Moderna intends to share consented samples with approved research institutions across the UK and Europe to benefit the wider life sciences ecosystem.

"We are delighted to mark this important milestone in our commitment to developing a mRNA research, development, and manufacturing facility in the UK.", said Darius Hughes, UK General Manager at Moderna. "We would like to thank our partners at Merit for constructing the off-site components of these state-of-the-art laboratories, which will play a key role in our search for new vaccines and therapeutics."

The MITC, which will also contain a manufacturing facility, is being constructed as part of Moderna's ten-year strategic partnership with the UK government and is anticipated to bring hundreds of jobs to the region. As part of the strategic partnership, Moderna is also working with academic and NHS partners across the four nations, bringing research, clinical trials, and skills development to many parts of the UK.

The clinical labs will begin operations in 2024, with the manufacturing facility expected to be completed in 2025.

Attributable quotes

Philippa Harvey, Director of the COVID Vaccine Unit at UKHSA said: "Working with industry is an integral part of our strategy to protect the nation's health and provide the UK with greater resilience against a future pandemic. The construction of Moderna's clinical laboratories in Harwell, Oxfordshire, is an important milestone in our 10-year partnership with Moderna and for life sciences in the UK."

Stuart Grant, Chief Executive of Harwell Campus said: "The delivery of these prefabricated laboratories is another fantastic example of innovative UK engineering being deployed at Harwell Campus. We are excited to take such a significant step towards completing the Moderna Innovation and Technology Centre and enabling such crucial research."

Tony Wells, CEO at Merit said: "It's incredibly exciting to see the offsite components of this facility leave our Cramlington factory for Harwell, Oxfordshire. Ultimately, our team has pioneered a high-

quality, specialised offsite solution that will bring highly advanced technology and medicines to market to help protect public health across the UK.”

ENDS

Notes to editors:

About Moderna

In over 10 years since its inception, Moderna (known in the UK as Moderna Biotech Distributer UK Ltd) has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. To learn more, visit www.modernatx.co.uk

Harwell Science and Innovation Campus

Harwell is the UK's leading science and innovation campus, where government, academia and industry work together to solve the critical problems facing our planet. The campus is home to £3bn national facilities and 6,000 colleagues committed to scientific discovery and understanding.

Moderna is the latest organisation to join Harwell's thriving Health Tech cluster which has grown to over 70 life science organisations since it launched in 2016.

The campus' unique combination of expertise in the development of vaccines and mRNA technologies includes: Europe's largest collection of open access, publicly funded scientific facilities, such as The Rosalind Franklin Institute and the Nucleic Acid Therapy Accelerator and commercial organisations including: Catalent, Vaccitech, NeoVac and Nanovation Therapeutics.

Harwell is managed and developed by a joint venture between the Science and Technology Facilities Council, the UK Atomic Energy Authority and the private sector investor, Brookfield.

Follow us on twitter and LinkedIn @HarwellCampus, or learn more here www.harwellcampus.com

About Merit

Merit is the UK's first industrialised construction and digital manufacturing specialist and prides itself on its ability to design and engineer-controlled environment solutions for the healthcare, biotech, pharmaceutical, semiconductor, aerospace and nuclear sectors, specialising in the delivery of complex cleanroom construction and M&E services that require stringent regulatory approvals.

Merit has developed a range of market specific proprietary 'DFM&A Platform designs' through 4D BIM and vertically integrated digitally manufacturing to deliver construction through an entirely new 'clean sheet of paper' approach focused on productivity, sustainability, and successful repeatable project

outcomes. Merit believes its FLEXI POD® and UltraPOD®+ products are the first truly disruptive I4.0 industrialised construction platforms to be demonstrated in operation.

Headquartered in Northumberland, it employs over 300 people in the UK and owns further facilities in London and Scotland. For further information visit www.merit.co.uk

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: construction of the Moderna Innovation and Technology Centre and Moderna's ten-year strategic partnership with the UK government; Moderna's aim for the facility to provide the UK public with access to domestically manufactured mRNA respiratory vaccines, pending assessment and licensure; the anticipated creation of jobs during construction and operation of the facility; and expected timing for the Drug Substance and Manufacturing facility to become operational. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

Moderna contact:

Emma Gilgunn-Jones
Director, Communications
emma.gilgunn-jones@modernatx.com

Harwell contact:

Dan Metcalfe
Director of Communications
dan.metcalfe@harwellcampus.com

Merit contact:

Camilla Bailey
Marketing Assistant
camilla.bailey@merit.co.uk

SOURCE: Moderna, Inc.